How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines
By: Carl E. Orringer
References
- Graham R Mancher M Miller Wolman D Greenfield S Steinberg E editors; Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines Clinical Practice guidelines we can trust Washington, D.C. National Academies Press (US) 2011 290 p
- Stone NJ Robinson JG Lichtenstein AH American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2014 Jun 24 129 25 Suppl 2 S1 45
- Khera AV Won HH Peloso GM Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia J Am Coll Cardiol 2016 Jun 7 67 22 2578 89
- Teslovich TM Musunuru K Smith AV Biological, clinical and population relevance of 95 loci for blood lipids Nature 2010 Aug 5 466 7307 707 13
- Talmud PJ Shah S Whittall R Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study Lancet 2013 Apr 13 381 9874 1293 301
- de Ferranti SD Rodday AM Mendelson MM Wong JB Leslie LK Sheldrick RC Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES) Circulation 2016 Mar 15 133 11 1067 72
- Do R Stitziel NO Won HH Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction Nature 2015 Feb 5 518 7537 102 6
- Benn M Watts GF Tybjærg-Hansen A Nordestgaard BG Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217 Eur Heart J 2016 May 1 37 17 1384 94
- Leiden Open (source) Variation Database [Internet] Netherlands Leiden University Medical Center c2004–2018 Graphs & statistics on gene LDLR; 2018 [cited 2018 Sep 28]. Available from: http://databases.lovd.nl/shared/genes
- Wintjens R Bozon D Belabbas K Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France J Lipid Res 2016 Mar 57 3 482 91
- Robinson JG Huijgen R Ray K Persons J Kastelein JJ Pencina MJ Determining When to Add Nonstatin Therapy: A Quantitative Approach J Am Coll Cardiol 2016 Dec 6 68 22 2412 21
- Perak AM Ning H de Ferranti SD Gooding HC Wilkins JT Lloyd-Jones DM Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype Circulation 2016 Jul 5 134 1 9 19
- Pérez de Isla L Alonso R Mata N Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study) Circulation 2017 May 30 135 22 2133 44
- Versmissen J Oosterveer DM Yazdanpanah M Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 2008 Nov 11 337 a2423
- Besseling J Hovingh GK Huijgen R Kastelein JJ Hutten BA Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality J Am Coll Cardiol 2016 Jul 19 68 3 252 60
- Shepherd J Cobbe SM Ford I Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 1995 Nov 16 333 20 1301 7
- Vallejo-Vaz AJ Robertson M Catapano AL Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Circulation Circulation 2017 Nov 14 136 20 1878 91
- Cannon CP Blazing MA Giugliano RP IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes N Engl J Med 2015 Jun 18 372 25 2387 97
- Huijgen R Abbink EJ Bruckert E Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial Clin Ther 2010 Apr 32 4 615 25
- Kastelein JJ Ginsberg HN Langslet G ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 2015 Nov 14 36 43 2996 3003
- Raal FJ Honarpour N Blom DJ .; TESLA Investigators Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 2015 Jan 24 385 9965 341 50
- Sabatine MS Giugliano RP Keech AC .; FOURIER Steering Committee and Investigators Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease N Engl J Med 2017 May 4 376 18 1713 22
-
Steg
PG
The ODYSSEY OUTCOMES Trial: Alirocumab in patients after acute coronary syndrome
Presented at: American College of Cardiology 67th Annual Scientific Session & Expo
2018 Mar 10 Orlando, Florida - Silverman MG Ference BA Im K Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis JAMA 2016 Sep 27 316 12 1289 97
- Orringer CE Jacobson TA Saseen JJ Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association J Clin Lipidol. 2017 Jul - Aug 11 4 880 90
- Lloyd-Jones DM Morris PB Ballantyne CM 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways J Am Coll Cardiol 2017 Oct 3 70 14 1785 822
- Simon JS Karnoub MC Devlin DJ Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment Genomics 2005 Dec 86 6 648 56
- Tsimikas S A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies J Am Coll Cardiol 2017 Feb 14 69 6 692 711
- Leebmann J Roeseler E Julius U .; Pro(a)LiFe Study Group Lipoprotein apheresis in patients with maximumly tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study Circulation 2013 Dec 17 128 24 2567 76
- Whelton PK Carey RM Aronow WS 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Hypertension 2018 Jun 71 6 1269 324
- Grundy SM Stone NJ Bailey AL 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J Am Coll Cardiol. 2018 Nov 3 pii: S0735-1097(18)39033-8. [Epub ahead of print]
DOI: https://doi.org/10.14797/mdcj-15-1-16 | Journal eISSN: 1947-6108
Language: English
Page range: 16 - 22
Published on: Jan 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2019 Carl E. Orringer, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.